Antibiotic resistance is tightening its grip on global healthcare, but the pipeline of truly new treatments remains thin.
That imbalance — rising need, limited innovation — has become a defining theme in infectious disease biotech. And it’s one that Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) Ltd is aiming to tackle with a new class of synthetic anti-infectives now advancing through late-stage trials.
With antimicrobial resistance increasingly being framed as a global health crisis, Recce is positioning itself not just as another antibiotic developer, but as a company attempting to redefine the category altogether. As CEO James Graham noted in a recent investor webinar, Recce set out to “identify a compound that works, and keeps on working with repeated use — one of the greatest challenges of antibiotic resistance today”.
The result is Recce 327 (R327), a synthetic, broad-spectrum anti-infective designed to rapidly kill bacteria — including drug-resistant strains — without driving the same resistance pathways as conventional antibiotics. The timing is critical, given the lack of innovation in antibiotic development at a time of growing threat.
“According to the World Health Organization, we are clinically the most advanced new class of antibiotics in the world, and in fact the first new class of antibiotics in over 40 years,” Graham said.
A late-stage program targeting a stubborn global problem
The centrepiece of Recce’s current strategy is its lead candidate R327, particularly in a gel formulation targeting diabetic foot infections — a notoriously difficult condition to treat.
Chief medical adviser Dr Alan Dunton laid out the rationale clearly: these infections are complex, poorly served by existing therapies, and often resistant to standard antibiotic approaches. Blood flow limitations, high bacterial loads and inconsistent treatment standards make them a persistent global challenge.
Recce’s approach is notably different. Rather than relying on systemic delivery, the gel is applied directly to the wound — bypassing circulation issues entirely.
“It has a broad spectrum of activity and it’s a perfect compound to use in this type of situation, where you often don’t even know what bacteria you’re treating,” Dunton said. “It’s a first-line therapy that can be used right away.”
Clinical data so far has been encouraging. In a phase 2 study, 86% of patients achieved a successful response after seven days of treatment, rising to 93% after 14 days — a result Dunton described as “really astounding” for an open-label trial.
That dataset has supported progression into a phase 3 trial now under way in Indonesia, targeting around 300 patients. An interim analysis is expected once roughly half the cohort is enrolled.
Why Indonesia — and why it matters
The choice of Indonesia is more than logistical: it reflects both medical need and commercial strategy.
With a population of around 280 million and a high prevalence of diabetes, Indonesia represents a significant market for diabetic foot treatments. More importantly, regulatory approval in one ASEAN country can open pathways across the broader region.
Local partner Etana’s CEO Nathan Tirtana described the collaboration as both a clinical and strategic milestone, noting that it “will allow the Indonesian patient to get the treatment, and will also tremendously help the clinician to treat the patient better with Recce technology”.
The involvement of Siloam Hospitals — one of Indonesia’s largest private healthcare networks — further underscores the scale of the trial infrastructure and patient access.
For investors, this regional strategy is critical. Rather than pursuing the traditional (and often slower) US-first pathway, Recce is aiming to establish early commercialisation in ASEAN, then expand outward.
Beyond the clinic: Defence and biodefence interest
Another layer of the Recce story — and one that may not be fully appreciated by the market — is its engagement with the US government.
Through multiple programs with the Department of Defense, R327 is being evaluated for use in battlefield and biodefence scenarios, including burn wounds, blast injuries and infections caused by high-risk pathogens.
David Lasseter of Horizons Global Solutions, a former US deputy assistant secretary of defense who is now working with Recce on its commercialisation strategy, said the technology aligns closely with evolving military needs.
“When we talk about providing the best capabilities, we also talk about doing this at the point of care — doing this on the battlefield to provide a capability as quickly as possible to the warfighter,” Lasseter said.
This includes a congressionally funded program developing a room-temperature-stable hydrogel for field use, as well as cooperative research agreements targeting Category A and B biological threats.
These programs are not just scientific validation — they also bring non-dilutive funding and potential long-term procurement pathways, a combination that is relatively rare in early-stage biotech.
A platform play in a stagnant field
Stepping back, Recce’s broader pitch is less about a single product and more about a platform.
Chairman John Prendergast framed the opportunity in stark terms: antibiotic innovation has effectively stalled, with only two truly new chamical classes emerging in the past decade.
Prendergast pointed to the scale of the problem, noting that antibiotic-resistant infections cause nearly 5 million deaths globally. Moreover, “roughly 75% of antibiotics are derived from existing drugs, and it’s inevitable that bacteria will develop resistance to these newly derived antibiotics.
“The antibacterial pipeline is in crisis,” he added, pointing to both a lack of innovation and the inevitability of resistance in existing drug classes.
Against that backdrop, Recce’s synthetic polymer platform — which targets bacterial energy production — is positioned as a fundamentally different approach.
Preclinical data show that across hundreds of multi-drug-resistant bacterial isolates, Recce’s compounds demonstrated consistent efficacy, with no observed resistance development in repeated testing.
The company is also exploring multiple delivery formats — including IV, inhalation and topical — opening pathways into hospital-acquired pneumonia, tuberculosis and other high-burden indications.
The bigger picture for investors
Recce is now operating on several fronts simultaneously:
- A phase 3 registrational trial in a high-need market
- Expanding international partnerships and regulatory pathways
- Active US government programs in biodefence and combat medicine
- A broader pipeline targeting multi-billion-dollar infectious disease markets
Perhaps most importantly, the company is moving closer to a potential commercial inflection point. As Graham noted, its products are “on track to be commercially available later this year” — a milestone that would mark a significant transition from development-stage biotech to revenue-generating player.
That timeline will be one to watch closely, as the company looks to convert years of development into tangible market entry. As Prendergast concluded: “Recce is a pioneer, certainly — but we want to become a global leader in the anti-infective space, and we truly represent the first broad-spectrum-effective antibiotic/anti-infective in over 40 years.”
Watch the webinar below:
